CrystecPharma is pleased to announce that CEO Paul Thorning has been invited to pitch at RespireX 2026, a Pitch Day event focused on innovation in respiratory medicine.
RespireX brings together emerging companies, clinical experts, and industry stakeholders to discuss and support the development of novel pulmonary therapies.
Commenting on the invitation, Paul Thorning said:
“I am honoured to have been invited to pitch at RespireX 2026. Crystec’s commitment to the development of new respiratory therapies is longstanding, and the event provides a valuable opportunity to engage with peers and experts working to advance novel respiratory and pulmonary therapies.”
CrystecPharma continues to support the development of innovative respiratory medicines through its expertise in particle engineering and formulation technologies